VALANX Biotech

Executive Summary

VALANX Biotech is an Austrian preclinical biotechnology company developing GoldenSite™, a proprietary protein conjugation platform designed to create next-generation antibody-drug conjugates (ADCs) and other protein-drug conjugates. Founded in 2021 and based in Vienna, the company aims to address key limitations of current conjugation technologies by enabling precise and stable attachment of payloads to proteins, thereby improving therapeutic index, safety, and efficacy. VALANX's platform has the potential to generate best-in-class ADCs for oncology and other indications. As a privately held, early-stage company, VALANX is focused on advancing its platform through preclinical validation and establishing partnerships with biopharma companies. While the company has not disclosed specific financials or valuation, its innovative approach positions it within the competitive ADC landscape. The near-term outlook depends on successful preclinical data generation and ability to attract collaborators or investors.

Upcoming Catalysts (preview)

• Q4 2026Preclinical proof-of-concept data release for lead ADC candidate60% success
• Q2 2027Partnership or licensing deal with a larger pharma company35% success
• Q3 2027Series A funding round announcement40% success